Core Insights - Alibaba Health and Beijing Meirsen Pharmaceutical Technology Development Co., Ltd. have formed a strategic partnership to collaborate in the field of innovative drugs for pediatric specialties, specifically focusing on the treatment of infantile hemangiomas with the drug Beimeijing (Timolol Maleate Gel) [1][2] Group 1: Product and Market Overview - Beimeijing is the world's first approved topical innovative drug for the treatment of proliferative superficial infantile hemangiomas, addressing a condition that affects an estimated 5% to 12% of infants globally, with superficial types accounting for nearly 70% of cases [1] - A meta-analysis by the Chinese Medical Association indicates that 25% to 69% of untreated children may experience long-term issues such as scarring and skin laxity, particularly affecting areas like the head and face, which can impact psychological health and social interactions [1] Group 2: Clinical Data and Efficacy - Phase III clinical trial results show that among 121 infants aged 1 to 6 months, 60.7% achieved clinical cure (Grade IV improvement) after 24 weeks of treatment, with an overall efficacy rate of 89.4%, demonstrating good safety and providing a new effective option for patients [1] Group 3: Strategic Initiatives and Future Plans - Beimeijing will be exclusively launched on Alibaba Health's platform on January 13, with plans to initiate the "Infant Hemangioma Care Program," which will integrate expert consultations, educational live streams, medication guidance communities, and public welfare projects to create a comprehensive care loop from awareness to recovery [2] - The collaboration aims to leverage Alibaba Health's ecosystem capabilities alongside Meirsen's expertise in pediatric specialty research, not only to provide a new drug but also to enhance health management solutions for children in China and promote industry standard upgrades [2] - Alibaba Health emphasizes that this strategic partnership is a key step in deepening its vertical disease management capabilities and implementing a patient-centered value strategy, aiming to maximize value through precise outreach, standardized treatment, and long-term management [2]

Core Insights - Alibaba Health and Beijing Melson Pharmaceutical Technology Development Co., Ltd. have formed a strategic partnership to collaborate in the field of innovative drugs for pediatric specialties, specifically focusing on the treatment of infantile hemangiomas with the topical drug Beimeijing® [1][2] Group 1: Product and Market Context - Beimeijing® (timolol maleate gel) is the world's first approved topical innovative drug for the treatment of proliferative superficial infantile hemangiomas, addressing a significant clinical need in the pediatric market [1] - The global incidence of infantile hemangiomas is estimated to be between 5% and 12%, with superficial types accounting for nearly 70% of cases [1] - A meta-analysis by the Chinese Medical Association indicates that 25% to 69% of untreated children may experience long-term issues such as scarring and skin laxity, particularly affecting areas like the head and face, which can impact psychological health and social interactions [1] Group 2: Clinical Trial Results - In a pivotal Phase III clinical trial involving 121 infants aged 1-6 months, Beimeijing® demonstrated a clinical cure rate of 60.7% and an overall efficacy rate of 89.4% after 24 weeks of treatment, with good safety profiles [2] Group 3: Strategic Initiatives and Future Plans - Beimeijing® is set to launch exclusively on Alibaba Health's platform on January 13, with plans to initiate the "Infant Hemangioma Care Program," which will include expert consultations, educational live streams, medication guidance communities, and charitable assistance projects [2] - The collaboration aims to integrate Alibaba Health's ecosystem capabilities with Melson's expertise in pediatric specialty research, enhancing health management solutions for children and promoting industry standards [2] - Alibaba Health emphasizes that this partnership is a key step in deepening its vertical disease management capabilities, focusing on patient-centered strategies to maximize the value of treatment solutions like Beimeijing® [2]

Core Viewpoint - Alibaba Health and Beijing Meirsen Pharmaceutical Technology Development Co., Ltd. have formed a strategic partnership to collaborate in the field of innovative drugs for pediatric specialties, specifically focusing on the first approved topical treatment for infantile hemangiomas, Betamethasone® [1][2] Group 1: Product Development and Clinical Data - Betamethasone® is the first topical gel specifically designed for treating infantile hemangiomas, addressing a significant clinical gap in pediatric care [2] - The product underwent twelve years of research and development, culminating in a successful Phase III clinical trial with a clinical cure rate of 60.7% and an overall efficacy rate of 89.4% among 121 infants aged 1-6 months [2] Group 2: Strategic Collaboration and Market Launch - The exclusive launch of Betamethasone® on Alibaba Health's platform is scheduled for January 13, with plans to initiate a "Care Program for Infantile Hemangiomas" that includes expert consultations, educational broadcasts, and community support [3] - The collaboration aims to integrate Alibaba Health's ecosystem capabilities with Meirsen's expertise in pediatric drug development, enhancing health management solutions for children [7]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 阿里健康信息技術有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00241 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

Core Insights - The recent online event "Technology Empowerment · Capital Breakthrough" hosted by Gelonghui revealed the annual list of outstanding companies, with Alibaba Health winning the "Annual Outstanding Medical Health Enterprise" award [1] Group 1: Award Recognition - Alibaba Health was recognized for its excellence in the medical health sector, receiving the "Annual Outstanding Medical Health Enterprise" award [1] - The award is based on multiple core dimensions including innovation capability, technological leadership, market influence, social value, and sustainable development [2] - The evaluation process involved quantitative data analysis and an expert review panel to determine the final results [2] Group 2: Participating Companies - The list of companies recognized in the 2025 Outstanding Company Awards includes notable names such as: - Alibaba Health (00241.HK) - Jinhuo Pharmaceutical Group (01110.HK) - Anxuyuan - Kangchen Pharmaceutical (01681.HK) - Baize Medical (02609.HK) - Ping An Good Doctor (01833.HK) - Gushengtang (02273.HK) - Weitai Medical-B (02235.HK) - Haijia Medical (06078.HK) - Xinwei Medical-B (06609.HK) [2]

Core Insights - The launch of Liv Urea Vitamin E Cream by ZhiYuan Pharmaceutical targets dry and cracked skin on hands and feet, utilizing urea and vitamin E as key ingredients to provide professional-grade daily skin care options [1][2] - Hand and foot cracking is a widespread skin issue, particularly prevalent in autumn and winter, with symptoms ranging from dryness and peeling to deep cracks and bleeding, which can severely impact daily life and work [2][3] - The demand for effective, safe, and easy-to-use professional topical products is highlighted by the need for moisturizing and skin barrier repair, as emphasized by dermatology experts [3] Company and Industry Overview - ZhiYuan Pharmaceutical has extensive experience in the field of skin health, focusing on the research and development of topical medications and functional skincare products [2] - The introduction of Liv Urea Vitamin E Cream represents an extension of the company's product line to address common skin care needs [2] - Alibaba Health serves as a platform for the launch, leveraging digital service capabilities to connect products with potential consumer groups more efficiently [2]

Core Viewpoint - The Hong Kong stock market's Hang Seng Technology Index achieved a remarkable annual increase of 23.45% in 2025, marking its best performance since 2020, with 22 out of 30 constituent stocks rising [1] Group 1: Stock Performance - Among the 30 constituent stocks, notable performers included Hua Hong Semiconductor, which surged by 243.19%, Horizon Robotics with a rise of 140.56%, and SMIC increasing by 124.69% [1] - Other significant gainers were JD Health at 97.51%, Alibaba-W at 77.50%, Xpeng Motors-W at 70.10%, Baidu Group-SW at 59.01%, and Tencent Music-SW at 58.44% [1][2] Group 2: Investment Preferences - The first tier of investment preference is in semiconductor manufacturing (Hua Hong, SMIC) and core AI chips (Horizon Robotics), reflecting a strong focus on hard technology and domestic substitution logic [1] - The second tier includes growth sectors such as smart electric vehicles (Xpeng, Li Auto), AI applications (Baidu, SenseTime), and digital health (JD Health), which benefit from industry trends but still face competitive and profitability uncertainties [1] - The third tier consists of value recovery in platform internet giants (Alibaba, Tencent) and mature applications (NetEase, Kuaishou, Tencent Music), with gains primarily driven by profit realization and value reassessment through dividends and buybacks, categorized as "high-quality mature assets" [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED – 1 – 股東特別大會結果 董事會欣然公佈，於2025年12月30日（星期二）下午二時正假座中國杭州市余杭區五 常街道文一西路969號菲住布渴酒店清風閣會議廳舉行之股東特別大會上，通告所 載之普通決議案（「決議案」）已以投票表決方式獲正式通過。有關決議案之投票表決 結果如下： | | 普通決議案 | 投票股份數目 （概約%） | | | --- | --- | --- | --- | | | | 贊成 | 反對 | | 1. | 確認、批准及追認就本公司與杭州阿里媽媽 | 2,399,254,357 | 100,000 | | | 軟件服務有限公司於2024年2月2日訂立之 | (99.99%) | (0.01%) | | | 2025年至2027年營銷推廣服務框架協議之截 | | | | | 至2026年3月 ...

Group 1 - In December, several leading pharmaceutical companies experienced significant executive changes, including Guoyao Holdings, BeiGene, and Zhendong Pharmaceutical [1][2] - Kexin Pharmaceutical announced the election of Li Hongfu as the chairman of its fourth board of directors on December 1 [1] - Kang En Bei reported that Jiang Yi resigned from multiple positions, including chairman, on December 6 due to work adjustments [1] Group 2 - WuXi AppTec appointed Tian Feng as the CEO and executive director, effective December 29, 2025 [2] - Alibaba Health announced the resignation of Zhu Shunyan as non-executive director and chairman, with current CEO Shen Difan taking over as chairman [2] - Sangfor Technologies reported the resignation of core technical personnel, Weng Zhibing, from all positions in its wholly-owned subsidiary on December 16 [2] Group 3 - Zhendong Pharmaceutical announced that Yang Lianmin resigned from his positions due to reaching retirement age on December 18 [2] - BeiGene appointed Dr. Wang Lai as president and global head of R&D, effective December 19 [2] - Guoyao Holdings announced Jin Bin as the new chairman on December 19, following the resignation of Zhao Bingxiang [2] Group 4 - Shijiazhuang Pharmaceutical Group reported that Zhang Cuilong stepped down from multiple roles, while Cai Lei was appointed as vice chairman and CEO on December 19 [3] - Weichuang Bio announced the appointment of Li Jianxun as general manager, while Chairman Lu Xianping stepped down from the general manager role on December 23 [3] - Shandong Pharmaceutical Glass reported that Chairman Hu Yonggang resigned from all positions due to age, with General Manager Zhang Jun taking over the chairman's responsibilities on December 24 [3]

Group 1 - The core product launched by China Resources Jiangzhong is a new formulation of the classic "Liuwei Dihuang Wan," transitioning from pill to paste form, designed for modern fast-paced lifestyles [1] - The traditional Chinese medicine market for kidney tonics is projected to reach 48.73 billion yuan in 2024, with a year-on-year growth of 9.2%, indicating a significant consumer trend towards health products that are efficient and convenient [1] - The new product features a portable design with independent packaging, enhancing convenience for users while also focusing on taste by incorporating honey for a sweet and slightly sour flavor [1] Group 2 - A representative from China Resources Jiangzhong emphasized that this innovation reflects the company's commitment to providing convenient health solutions and its role as a leader in the inheritance and innovation of traditional Chinese medicine [2] - Alibaba Health stated its role as a launch platform for new specialty drugs, aiming to provide consumers with easy access to health products, with many regions offering same-day or next-day delivery for the new product [2]